Medipex award winner recommended in NHS long COVID plan
5 August 2022
The screening tool is used to assess the severity of common persistent symptoms identified in patients after contracting Covid-19.
The Digital C19-YRS platform, from Medipex Awards winner Elaros, builds upon the world’s first clinically validated, condition-specific screening tool used to assess the severity of common persistent symptoms identified in patients after contracting Covid-19, a condition known as ‘long Covid’ or ‘post-Covid-19 syndrome’.
The self-reporting tool has been developed by clinical academics at The University of Leeds working at Leeds Teaching Hospital NHS Trust (LTHT) and has been recommended for routine use by NHS England in their National Guidance for post-Covid syndrome assessment clinics and also recognised by NICE in their rapid guidelines for managing the long-term effects of Covid-19.
Elaros won a Medipex award in the Management of Long Term Conditions category in 2021 in partnership with colleagues from LTHT when the system development was complete and being used by 27 NHS hospitals.
Román Rocha Lawrence, Director of Research & Development at Elaros said, “We’re thrilled to see the impact that our system is making. We want to continue to support patients with long Covid, and have plans to develop a health and well-being version for sufferers of Long Covid across the rest of the World, before the end of 2022.”
The NHS England plan for improving long Covid services provides an update on progress made on the 10 actions set out in the NHS long Covid plan for 2021/22 and sets out the framework for deploying the £90m committed by the NHS for long Covid services during this financial year.
For more information, visit the C19-YRS (Covid-19 Yorkshire Rehabilitation Scale) website.